Jasper Total Assets from 2010 to 2025

JSPRW Stock

USD 0.14 0.01 7.69%

Jasper Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 67.4 M in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2019-12-31

Previous Quarter

99.4 M

Current Value

79.9 M

Quarterly Volatility

26.8 M

Covid

Check Jasper Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jasper Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Selling General Administrative of 13.1 M or Other Operating Expenses of 40 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.31. Jasper financial statements analysis is a perfect complement when working with Jasper Therapeutics Valuation or Volatility modules.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Latest Jasper Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Jasper Therapeutics over the last few years. Total assets refers to the total amount of Jasper Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Jasper Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Jasper Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jasper Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 79.9 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Jasper Total Assets Regression Statistics

	Arithmetic Mean	42,476,556
	Geometric Mean	36,940,288
	Coefficient Of Variation	61.14
	Mean Deviation	21,471,890
	Median	27,211,000
	Standard Deviation	25,969,582
	Sample Variance	674.4T
	Range	71.5M
	R-Value	0.72
	Mean Square Error	348.8T
	R-Squared	0.52
	Significance	0
	Slope	3,923,132
	Total Sum of Squares	10116.3T

Jasper Total Assets History

	2025	67.4 M
	2024	79.9 M
	2023	94.9 M
	2022	48.4 M
	2021	93.7 M
	2020	23.4 M

Other Fundumenentals of Jasper Therapeutics

Intangibles To Total Assets

Jasper Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Capital Surpluse	Total Liab	Long Term Investments	Total Current Assets	Common Stock	Long Term Debt	Net Receivables	Long Term Debt Total	Net Invested Capital	Capital Stock	Net Working Capital	Current Deferred Revenue	Short Term Debt
Total Assets		0.86	-0.77	-0.98	-0.8	0.98	-0.41	0.78	0.32	0.49	1.0	-0.75	-0.41	-0.78	-0.41	0.98	0.58	1.0	-0.41	0.06
Total Stockholder Equity	0.86		-0.43	-0.86	-0.61	0.75	-0.28	0.42	-0.21	0.37	0.87	-0.34	-0.28	-0.67	-0.28	0.82	0.47	0.83	-0.28	0.07
Net Tangible Assets	-0.77	-0.43		0.76	0.93	-0.85	0.72	-0.89	-0.64	-0.73	-0.74	0.92	0.72	0.68	0.72	-0.84	-0.55	-0.79	0.72	-0.22
Net Debt	-0.98	-0.86	0.76		0.81	-0.95	0.52	-0.69	-0.26	-0.54	-0.99	0.69	0.52	0.8	0.52	-0.94	-0.49	-0.99	0.52	0.07
Retained Earnings	-0.8	-0.61	0.93	0.81		-0.86	0.77	-0.78	-0.37	-0.83	-0.79	0.81	0.77	0.85	0.77	-0.86	-0.4	-0.8	0.77	-0.16
Accounts Payable	0.98	0.75	-0.85	-0.95	-0.86		-0.47	0.87	0.48	0.58	0.97	-0.85	-0.47	-0.82	-0.47	0.97	0.54	0.97	-0.47	0.05
Short Term Investments	-0.41	-0.28	0.72	0.52	0.77	-0.47		-0.34	-0.18	-0.85	-0.41	0.44	1.0	0.55	1.0	-0.46	-0.16	-0.45	1.0	0.1
Capital Surpluse	0.78	0.42	-0.89	-0.69	-0.78	0.87	-0.34		0.74	0.5	0.75	-0.96	-0.34	-0.61	-0.34	0.84	0.63	0.78	-0.34	0.36
Total Liab	0.32	-0.21	-0.64	-0.26	-0.37	0.48	-0.18	0.74		0.21	0.29	-0.8	-0.18	-0.24	-0.18	0.35	0.26	0.36	-0.18	0.03
Long Term Investments	0.49	0.37	-0.73	-0.54	-0.83	0.58	-0.85	0.5	0.21		0.49	-0.49	-0.85	-0.72	-0.85	0.53	0.19	0.48	-0.85	-0.03
Total Current Assets	1.0	0.87	-0.74	-0.99	-0.79	0.97	-0.41	0.75	0.29	0.49		-0.72	-0.41	-0.79	-0.41	0.97	0.55	0.99	-0.41	0.01
Common Stock	-0.75	-0.34	0.92	0.69	0.81	-0.85	0.44	-0.96	-0.8	-0.49	-0.72		0.44	0.65	0.44	-0.8	-0.48	-0.76	0.44	-0.22
Long Term Debt	-0.41	-0.28	0.72	0.52	0.77	-0.47	1.0	-0.34	-0.18	-0.85	-0.41	0.44		0.55	1.0	-0.46	-0.16	-0.45	1.0	0.1
Net Receivables	-0.78	-0.67	0.68	0.8	0.85	-0.82	0.55	-0.61	-0.24	-0.72	-0.79	0.65	0.55		0.55	-0.74	-0.03	-0.75	0.55	0.22
Long Term Debt Total	-0.41	-0.28	0.72	0.52	0.77	-0.47	1.0	-0.34	-0.18	-0.85	-0.41	0.44	1.0	0.55		-0.46	-0.16	-0.45	1.0	0.1
Net Invested Capital	0.98	0.82	-0.84	-0.94	-0.86	0.97	-0.46	0.84	0.35	0.53	0.97	-0.8	-0.46	-0.74	-0.46		0.66	0.97	-0.46	0.24
Capital Stock	0.58	0.47	-0.55	-0.49	-0.4	0.54	-0.16	0.63	0.26	0.19	0.55	-0.48	-0.16	-0.03	-0.16	0.66		0.58	-0.16	0.65
Net Working Capital	1.0	0.83	-0.79	-0.99	-0.8	0.97	-0.45	0.78	0.36	0.48	0.99	-0.76	-0.45	-0.75	-0.45	0.97	0.58		-0.45	0.03
Current Deferred Revenue	-0.41	-0.28	0.72	0.52	0.77	-0.47	1.0	-0.34	-0.18	-0.85	-0.41	0.44	1.0	0.55	1.0	-0.46	-0.16	-0.45		0.1
Short Term Debt	0.06	0.07	-0.22	0.07	-0.16	0.05	0.1	0.36	0.03	-0.03	0.01	-0.22	0.1	0.22	0.1	0.24	0.65	0.03	0.1

Click cells to compare fundamentals

About Jasper Therapeutics Financial Statements

Jasper Therapeutics investors use historical fundamental indicators, such as Jasper Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jasper Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	79.9 M	67.4 M
Intangibles To Total Assets	(0.02)	(0.02)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC